See ratings and reviews when you sign up for an account.

A Prospective, Multicenter, Open-Label, Randomized Clinical Study to Evaluate the Duration of Treatment With Ertapenem in Acute Attacks of Sigmoid Diverticulitis

This study is currently Recruiting

February 2006 By Klinikum Hanover-Siloah Hospital

First Recieved on November 29, 2004

Last Updated on February 12, 2006

Sponsor: Klinikum Hanover-Siloah Hospital
Information provided by: Klinikum Hanover-Siloah Hospital
Identifier: NCT00097734


The purpose of this study is to compare the efficacy (by assessing the clinical success of treatment) of intravenous antibiotic therapy with ertapenem in patients with acute attacks of sigmoid diverticulitis for 4 vs. 7 days.

Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Educational/Counseling/Training


Ages Eligible for Study:18 Years
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No

Inclusion Criteria: - At least three of the following signs or symptoms of an acute attack of sigmoid diverticulitis must be present: *Fever (body temperature > 38?C, sublingual), *Abdominal tenderness, *Leukocytosis (leukocytes > 10,000/?l) and left shift of the differential blood count (>1% band forms), *Elevated CRP (> 20 mg/l) - Evidence of sigmoid diverticulitis by contrast enema - CT evidence of wall thickening in the sigmoid intestine - Decision in favor of conservative therapy on the basis of the case history and diagnosis Exclusion Criteria: - Contraindication for the use of the study medication or other beta-lactam antibiotics, e.g. patients with advanced renal impairment or patients requiring hemodialysis - Antibiotic therapy in the two weeks prior to the start of the study - Patients with an advanced incurable disease - Patients with a hematologic/oncologic disease (leukemia, lymphoma) - Patients on immunosuppressants - Complications of sigmoid diverticulitis leading to an immediate indication for surgery - Patients who have hypersensitivity to beta-lactam antibiotics - Female patients who are pregnant or nursing or who could become pregnant during the study - Participation in another clinical study or use of another study drug within the four weeks prior to enrollment in the study or use of another drug during the study - Each patient can be enrolled only once in the study


  • Investigator: Ferdinand Koeckerling, Prof. Dr. - Study Chair - Klinikum Hanover-Siloah hospital and Nordstadt hospital- Surgical Department


  • Klinikum Hannover- Krankenhaus Siloah

    Hannover, 30449 Germany

Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.